Liver cirrhosis is a major cause of liver-related morbidity and mortality worldwide and is characterized by extensive fibrosis. However, no effective diagnostic and therapeutic strategy are available owing to poorly characterized molecular etiology. To obtain a better understanding of the molecular mechanisms involved in disease pathogenesis and enable the discovery of therapeutic targets, iTRAQ-based quantitative proteomic was applied using healthy and cirrhotic human liver.